Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
The Board of Directors
BioMarin Pharmaceutical Inc.:
We consent to the use of our reports dated February 27, 2019 with respect to the consolidated balance sheets of BioMarin Pharmaceutical Inc. and subsidiaries as of December 31, 2018 and 2017 and the related consolidated statements of operations, comprehensive loss, stockholders’ equity and cash flows for each of the years in the three-year period ended December 31, 2018, and the effectiveness of internal control over financial reporting as of December 31, 2018, incorporated by reference herein. Our report refers to a change in the method of accounting for revenue due to the adoption of Accounting Standards Codification 606,Revenue from Contracts with Customers.
/s/ KPMG LLP
San Francisco, California
October 16, 2019